Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Acrylates
Aged
Angiotensin Receptor Antagonists
/ pharmacology
Angiotensin-Converting Enzyme Inhibitors
/ pharmacology
Antihypertensive Agents
/ therapeutic use
Blood Pressure
Fructose
/ pharmacology
Humans
Hypertension
/ drug therapy
Imidazoles
Losartan
/ pharmacology
Metabolic Syndrome
/ drug therapy
Middle Aged
Thiophenes
Uric Acid
Journal
Journal of the renin-angiotensin-aldosterone system : JRAAS
ISSN: 1752-8976
Titre abrégé: J Renin Angiotensin Aldosterone Syst
Pays: England
ID NLM: 100971636
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
05
2021
accepted:
13
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Excessive intake of fructose increases serum uric acid concentration. Hyperuricemia induces a negative effect on atherosclerosis and inflammation. Hyperuricemia is common in patients with arterial hypertension. Several antihypertensive drugs including diuretics increase serum uric acid concentration. In contrast, the angiotensin II receptor antagonist (ARB) losartan was found to lower serum uric acid though it may increase renal excretion while other ARBs showed mostly a neutral effect. In this study, effects of two AT1 receptor antagonists losartan and eprosartan on serum uric acid changes induced by oral fructose load were directly compared. The randomized, crossover, head-to-head comparative study comprised 16 ambulatory patients (mean age 64.5 ± 9.8 years). The patients fulfilled AHA/NHLBI 2005 criteria of metabolic syndrome. A daily single morning dose of each study drug (50 mg of losartan or 600 mg of eprosartan) was given during two 3-month periods in a random order separated by 2-week washout time. The oral fructose tolerance test (OFTT) was performed at baseline and after each two 3-onth treatment periods. Before and during OFTT, urine excretion of uric acid and creatinine was assessed in the first morning portion of urine. Blood samples for the measurement of serum uric acid and lipids were taken at baseline and 30, 60, and 120 minutes after oral intake of 75 g of fructose. After 3-month treatment with eprosartan and losartan, both systolic and diastolic blood pressure decreased significantly and to a similar extent. After the treatment, serum uric acid and its baseline and postfructose urine excretion were unchanged. No significant changes of plasma lipids before and after OFTT were observed throughout the study. The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion. This trial is registered with NCT04954560.
Identifiants
pubmed: 34527078
doi: 10.1155/2021/2214978
pmc: PMC8413080
doi:
Substances chimiques
Acrylates
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Antihypertensive Agents
0
Imidazoles
0
Thiophenes
0
Uric Acid
268B43MJ25
eprosartan
2KH13Z0S0Y
Fructose
30237-26-4
Losartan
JMS50MPO89
Banques de données
ClinicalTrials.gov
['NCT04954560']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2214978Informations de copyright
Copyright © 2021 Anna Masajtis-Zagajewska et al.
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Hum Hypertens. 2006 Jan;20(1):45-50
pubmed: 16281062
Circulation. 1969 Jan;39(1):121-5
pubmed: 5782799
Am J Transl Res. 2020 Jul 15;12(7):3167-3181
pubmed: 32774692
Eur J Clin Invest. 1973 Sep;3(5):436-41
pubmed: 4772339
Nephrol Dial Transplant. 2001 May;16(5):1034-7
pubmed: 11328912
J Pharmacol Exp Ther. 1996 Jan;276(1):125-9
pubmed: 8558420
Intern Med. 2002 Oct;41(10):793-7
pubmed: 12412998
Arthritis Rheum. 2000 Jan;43(1):103-8
pubmed: 10643705
J Hypertens. 1995 Nov;13(11):1343-51
pubmed: 8984133
Integr Blood Press Control. 2019 Dec 24;12:43-62
pubmed: 31920373
Clin Chem. 1985 Jul;31(7):1141-3
pubmed: 4006182
Nutr Metab. 1970;12(4):193-219
pubmed: 5494658
Acta Med Scand. 1972 May;191(5):433-9
pubmed: 4555618
Pharmacotherapy. 1999 Apr;19(4 Pt 2):73S-78S
pubmed: 10213525
Am J Gastroenterol. 2003 Feb;98(2):466-70
pubmed: 12591070
J Hypertens. 2001 Oct;19(10):1855-60
pubmed: 11593107
J Clin Invest. 1978 Jan;61(1):209-20
pubmed: 618911
Curr Opin Rheumatol. 2002 May;14(3):281-6
pubmed: 11981327
Am J Hypertens. 2006 Feb;19(2):208-13
pubmed: 16448895
Hypertension. 2021 Feb;77(2):383-392
pubmed: 33356394
Lancet. 2009 Aug 15;374(9689):525-33
pubmed: 19683638
Proc Soc Exp Biol Med. 1956 Feb;91(2):321-3
pubmed: 13297789
Nucleic Acids Res. 2002 Jan 1;30(1):412-5
pubmed: 11752352
Clin Ther. 2001 Aug;23(8):1166-79
pubmed: 11558856
Am J Cardiol. 1995 Apr 15;75(12):793-5
pubmed: 7717281
Hypertension. 1995 Apr;25(4 Pt 1):602-9
pubmed: 7721404
Metabolism. 1980 Apr;29(4):303-5
pubmed: 6990170
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
J Pharmacol Exp Ther. 1996 Jan;276(1):187-93
pubmed: 8558429
J Hypertens. 1999 Jul;17(7):1033-9
pubmed: 10419078